Cite
HARVARD Citation
Myers, R. et al. (2022). Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. Journal of clinical oncology. 40 (9), pp. 932-944. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Myers, R. et al. (2022). Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. Journal of clinical oncology. 40 (9), pp. 932-944. [Online].